News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
283,201 Results
Type
Article (8904)
Company Profile (36)
Press Release (274261)
Section
Business (99898)
Career Advice (514)
Deals (18448)
Drug Delivery (25)
Drug Development (26088)
Employer Resources (36)
FDA (5344)
Job Trends (5987)
News (149724)
Policy (10414)
Tag
2024 BioCapital Digital (2)
2024 BioForest Digital (2)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (1)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
Academia (680)
Accelerated approval (3)
Adcomms (11)
Allergies (18)
Alliances (22224)
ALS (42)
Alzheimer's disease (568)
Antibody-drug conjugate (ADC) (44)
Approvals (5333)
Artificial intelligence (121)
Autoimmune disease (3)
Automation (8)
Bankruptcy (103)
Best Places to Work (4824)
BIOSECURE Act (1)
Biosimilars (13)
Biotechnology (36)
Bladder cancer (16)
Brain cancer (12)
Breast cancer (88)
Cancer (757)
Cardiovascular disease (36)
Career advice (436)
Career pathing (5)
CAR-T (55)
Cell therapy (176)
Cervical cancer (7)
Clinical research (21492)
Collaboration (408)
Compensation (136)
Complete response letters (4)
COVID-19 (670)
CRISPR (16)
C-suite (109)
Cystic fibrosis (34)
Data (645)
Decentralized trials (1)
Depression (6)
Diabetes (58)
Diagnostics (2862)
Digital health (10)
Diversity (1)
Diversity, equity & inclusion (12)
Drug discovery (50)
Drug pricing (15)
Drug shortages (4)
Duchenne muscular dystrophy (38)
Earnings (44745)
Editorial (4)
Employer branding (6)
Employer resources (36)
Events (43686)
Executive appointments (362)
FDA (5741)
Featured Employer (10)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (3)
Funding (368)
Gene editing (37)
Generative AI (15)
Gene therapy (122)
GLP-1 (169)
Government (1057)
Grass and pollen (1)
Guidances (24)
Healthcare (6872)
Huntington's disease (7)
IgA nephropathy (9)
Immunology and inflammation (23)
Indications (8)
Infectious disease (707)
Inflammatory bowel disease (39)
Inflation Reduction Act (4)
Influenza (9)
Intellectual property (26)
Interviews (61)
IPO (8982)
IRA (5)
Job creations (1360)
Job search strategy (396)
Kidney cancer (6)
Labor market (7)
Layoffs (148)
Leadership (5)
Legal (2500)
Liver cancer (20)
Lung cancer (100)
Lymphoma (62)
Machine learning (2)
Management (14)
Manufacturing (103)
MASH (31)
Medical device (5243)
Medtech (5247)
Mergers & acquisitions (9731)
Metabolic disorders (168)
Multiple sclerosis (13)
NASH (10)
Neurodegenerative disease (28)
Neuropsychiatric disorders (2)
Neuroscience (736)
NextGen: Class of 2025 (2262)
Non-profit (1582)
Northern California (1093)
Now hiring (2)
Obesity (82)
Opinion (76)
Ovarian cancer (29)
Pain (26)
Pancreatic cancer (24)
Parkinson's disease (48)
Partnered (10)
Patents (40)
Patient recruitment (37)
Peanut (12)
People (29181)
Pharmaceutical (8)
Pharmacy benefit managers (1)
Phase I (6426)
Phase II (9316)
Phase III (7707)
Pipeline (509)
Podcasts (12)
Policy (12)
Postmarket research (733)
Preclinical (2426)
Press Release (70)
Prostate cancer (36)
Psychedelics (7)
Radiopharmaceuticals (136)
Rare diseases (141)
Real estate (2463)
Recruiting (11)
Regulatory (7492)
Reports (19)
Research institute (816)
Resumes & cover letters (76)
Rett syndrome (2)
RSV (3)
Schizophrenia (22)
Series A (62)
Series B (44)
Service/supplier (2)
Sickle cell disease (16)
Southern California (799)
Special edition (5)
Sponsored (7)
Startups (1599)
Stomach cancer (5)
Supply chain (11)
The Weekly (12)
United States (8775)
Vaccines (131)
Venture capitalists (10)
Webinars (5)
Weight loss (39)
Women's health (4)
Worklife (1)
Date
Today (84)
Last 7 days (397)
Last 30 days (1432)
Last 365 days (15557)
2025 (2771)
2024 (15896)
2023 (18316)
2022 (24500)
2021 (26544)
2020 (24501)
2019 (18444)
2018 (13884)
2017 (13226)
2016 (12004)
2015 (14912)
2014 (11312)
2013 (9071)
2012 (9763)
2011 (10271)
2010 (9791)
Location
Africa (236)
Alabama (25)
Alaska (3)
Arizona (73)
Arkansas (5)
Asia (15595)
Australia (2163)
California (2309)
Canada (812)
China (139)
Colorado (91)
Connecticut (129)
Delaware (52)
Europe (33580)
Florida (318)
Georgia (38)
Idaho (34)
Illinois (176)
India (7)
Indiana (96)
Iowa (2)
Japan (73)
Kansas (33)
Kentucky (12)
Louisiana (6)
Maine (42)
Maryland (311)
Massachusetts (1866)
Michigan (122)
Minnesota (149)
Mississippi (1)
Missouri (26)
Montana (17)
Nebraska (16)
Nevada (25)
New Hampshire (37)
New Jersey (641)
New Mexico (10)
New York (687)
North Carolina (436)
North Dakota (4)
Northern California (1093)
Ohio (94)
Oklahoma (5)
Oregon (6)
Pennsylvania (450)
Puerto Rico (1)
Rhode Island (17)
South America (352)
South Carolina (3)
Southern California (799)
Tennessee (45)
Texas (275)
Utah (75)
Virginia (50)
Washington D.C. (14)
Washington State (202)
West Virginia (2)
Wisconsin (27)
283,201 Results for "accelerator corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Accelerated approval
Inspector General Questions FDA’s Accelerated Approval for Biogen, Sarepta Drugs
An OIG report zeroed in on what it said were three particularly problematic accelerated approvals: Biogen’s Aduhelm, Sarepta’s Exondys and Covis’ Makena.
January 15, 2025
·
2 min read
·
Tristan Manalac
Regulatory
Deep Dive: FDA’s Accelerated Approval Pathway Under Fire
In this deep dive
BioSpace
explores the opportunities and challenges presented by the FDA’s accelerated approval program.
November 18, 2024
·
2 min read
·
Heather McKenzie
Neurodegenerative disease
UniQure Clears Path to Accelerated Approval for Huntington’s Gene Therapy
In a Type B meeting, the FDA signified that it will allow uniQure to use a natural history control, the composite Unified Huntington’s Disease Rating Scale, and neurofilament light chain levels to support the accelerated approval of its gene therapy AMT-130.
December 10, 2024
·
2 min read
·
Tristan Manalac
Editorial
FDA’s Accelerated Approval Pathway Drives Momentum for Intractable, Fatal Diseases
Despite hotly debated biomarkers and failed or delayed confirmatory trials, the accelerated approval program has a track record of propelling R&D for some of medicine’s most challenging illnesses.
December 2, 2024
·
6 min read
·
Heather McKenzie
FDA
5 Accelerated Approvals Gone Wrong
Since its inception in 1992, the FDA’s accelerated approval pathway has helped shepherd nearly 300 new drugs to the market. However, recent years have seen a number of high-profile market withdrawals and failed confirmatory trials.
October 14, 2024
·
7 min read
·
Heather McKenzie
FDA
Evolving FDA Accelerated Approval Pathway Suffers Spate of Withdrawals
As therapies for rare and neurological diseases earn accelerated approval, experts laud the program’s intent while remaining concerned about confirmatory trials and clinical efficacy, especially as products greenlit under this pathway are pulled from the market.
October 28, 2024
·
7 min read
·
Heather McKenzie
Genetown
Neutron Therapeutics’ Accelerator Receives Final Acceptance at University of Birmingham’s High Flux Accelerator-Driven Neutron Facility
Neutron Therapeutics, a leading developer of accelerator-based neutron systems for targeted radiation therapy of solid tumors, today announced that its compact accelerator has received final acceptance for use at the University of Birmingham’s High Flux Accelerator-Driven Neutron Facility.
December 13, 2023
·
3 min read
Press Releases
Osivax Secures Strategic Funding to Accelerate the Development of its Influenza Vaccine Candidates
March 4, 2025
·
2 min read
Press Releases
FELDAN THERAPEUTICS ACCELERATES GROWTH WITH STRATEGIC INVESTMENT FROM LINEARIS VENTURES
February 18, 2025
·
2 min read
Press Releases
Adagio Medical Announces Strategic Restructuring to Accelerate US Pivotal IDE Trial and Product Innovation
March 3, 2025
·
5 min read
1 of 28,321
Next
